BACKGROUND: A variety of immune pathways can lead to graft-versus-host disease. A better understanding of the type of immune response causing graft-versus-host disease in defined clinical hematopoietic stem cell transplant settings is required to inform development of methods for monitoring patients and providing them tailored care. DESIGN AND METHODS: Twenty-five patients were recruited presenting with myeloid malignancies and treated with a reduced intensity conditioning transplant regimen with graft-versus-host disease prophylaxis comprising in vivo lymphocyte depletion with alemtuzumab and cyclosporin. A prospective study was performed of lymphocyte subset reconstitution in peripheral blood in relation to the incidence of graft-versus-host disease. RESULTS: Acute graft-versus-host disease was associated with significantly higher numbers of natural killer cells and donor-derived effector CD4 T cells (CD45RO(+) CD27(-)) early (day 30) after transplantation (p=0.04 and p=0.02, respectively). This association was evident before the emergence of clinical pathology in six out of seven patients. Although numbers of regulatory CD4 T cells (CD25(high) Foxp3(+)) were similar at day 30 in all patients, a significant deficit in those who developed acute graft-versus-host disease was apparent relative to effector CD4 T cells (median of 41 effectors per regulatory cell compared to 12 to 1 for patients without graft-versus-host disease) (p=0.03). By day 180, a functional regulatory CD4 T-cell population had expanded significantly in patients who developed chronic graft-versus-host disease, reversing the imbalance (median of 3 effectors per regulatory cell compared to 9.6 to 1 for patients without graft-versus-host disease) (p=0.018) suggesting no overt absence of immune regulation in the late onset form of the disease. CONCLUSIONS: Imbalance of effector and regulatory CD4 T cells is a signature of graft-versus-host disease in this transplantation protocol.
BACKGROUND: A variety of immune pathways can lead to graft-versus-host disease. A better understanding of the type of immune response causing graft-versus-host disease in defined clinical hematopoietic stem cell transplant settings is required to inform development of methods for monitoring patients and providing them tailored care. DESIGN AND METHODS: Twenty-five patients were recruited presenting with myeloid malignancies and treated with a reduced intensity conditioning transplant regimen with graft-versus-host disease prophylaxis comprising in vivo lymphocyte depletion with alemtuzumab and cyclosporin. A prospective study was performed of lymphocyte subset reconstitution in peripheral blood in relation to the incidence of graft-versus-host disease. RESULTS: Acute graft-versus-host disease was associated with significantly higher numbers of natural killer cells and donor-derived effector CD4 T cells (CD45RO(+) CD27(-)) early (day 30) after transplantation (p=0.04 and p=0.02, respectively). This association was evident before the emergence of clinical pathology in six out of seven patients. Although numbers of regulatory CD4 T cells (CD25(high) Foxp3(+)) were similar at day 30 in all patients, a significant deficit in those who developed acute graft-versus-host disease was apparent relative to effector CD4 T cells (median of 41 effectors per regulatory cell compared to 12 to 1 for patients without graft-versus-host disease) (p=0.03). By day 180, a functional regulatory CD4 T-cell population had expanded significantly in patients who developed chronic graft-versus-host disease, reversing the imbalance (median of 3 effectors per regulatory cell compared to 9.6 to 1 for patients without graft-versus-host disease) (p=0.018) suggesting no overt absence of immune regulation in the late onset form of the disease. CONCLUSIONS: Imbalance of effector and regulatory CD4 T cells is a signature of graft-versus-host disease in this transplantation protocol.
Authors: K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran Journal: Semin Hematol Date: 1991-07 Impact factor: 3.851
Authors: D Gallardo; J García-López; A Sureda; C Canals; C Ferra; J A Cancelas; J J Berlanga; S Brunet; C Boqué; M Picón; C Torrico; B Amill; R Martino; C Martínez; G Martín-Henao; A Domingo-Albós; A Grañena Journal: Bone Marrow Transplant Date: 1997-12 Impact factor: 5.483
Authors: R Champlin; W Ho; J Gajewski; S Feig; M Burnison; G Holley; P Greenberg; K Lee; I Schmid; J Giorgi Journal: Blood Date: 1990-07-15 Impact factor: 22.113
Authors: Aloysius Y L Ho; Antonio Pagliuca; Michelle Kenyon; Jane E Parker; Aleksandar Mijovic; Stephen Devereux; Ghulam J Mufti Journal: Blood Date: 2004-04-01 Impact factor: 22.113
Authors: Kouhei Yamashita; Uimook Choi; Patricia C Woltz; Susan F Foster; Michael C Sneller; Francis T Hakim; Daniel H Fowler; Michael R Bishop; Steven Z Pavletic; Marisa Tamari; Kathleen Castro; A John Barrett; Richard W Childs; Gabor G Illei; Susan F Leitman; Harry L Malech; Mitchell E Horwitz Journal: Blood Date: 2004-02-05 Impact factor: 22.113
Authors: Yuji Miura; Christopher J Thoburn; Emilie C Bright; Michele L Phelps; Tahiro Shin; Elizabeth C Matsui; William H Matsui; Sally Arai; Ephraim J Fuchs; Georgia B Vogelsang; Richard J Jones; Allan D Hess Journal: Blood Date: 2004-06-01 Impact factor: 22.113
Authors: Aaron E Foster; Marina Marangolo; Mary M Sartor; Stephen I Alexander; Min Hu; Kenneth F Bradstock; David J Gottlieb Journal: Blood Date: 2004-07-01 Impact factor: 22.113
Authors: Kazuyuki Murase; Haesook T Kim; O R Gregory Bascug; Yutaka Kawano; Jeremy Ryan; Ken-ichi Matsuoka; Matthew S Davids; John Koreth; Vincent T Ho; Corey Cutler; Philippe Armand; Edwin P Alyea; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Anthony Letai; Jerome Ritz Journal: Haematologica Date: 2014-05-23 Impact factor: 9.941
Authors: Nataliya P Buxbaum; Donald E Farthing; Natella Maglakelidze; Martin Lizak; Hellmut Merkle; Andrea C Carpenter; Brittany U Oliver; Veena Kapoor; Ehydel Castro; Gregory A Swan; Liliane M Dos Santos; Nicolas J Bouladoux; Catherine V Bare; Francis A Flomerfelt; Michael A Eckhaus; William G Telford; Yasmine Belkaid; Remy J Bosselut; Ronald E Gress Journal: JCI Insight Date: 2017-06-15
Authors: A Xhaard; H Moins-Teisserenc; M Busson; M Robin; P Ribaud; N Dhedin; S Abbes; M Carmagnat; V-D Kheav; G Maki; R Peffault de Latour; A Toubert; G Socié Journal: Bone Marrow Transplant Date: 2014-05-19 Impact factor: 5.483
Authors: Niwa Ali; Barry Flutter; Robert Sanchez Rodriguez; Ehsan Sharif-Paghaleh; Linda D Barber; Giovanna Lombardi; Frank O Nestle Journal: PLoS One Date: 2012-08-28 Impact factor: 3.240
Authors: Jeff K Davies; Lisa L Brennan; John R Wingard; Christopher R Cogle; Neena Kapoor; Ami J Shah; Bimalangshu R Dey; Thomas R Spitzer; Marcos de Lima; Laurence J Cooper; Peter F Thall; Richard E Champlin; Lee M Nadler; Eva C Guinan Journal: Clin Cancer Res Date: 2018-05-16 Impact factor: 12.531
Authors: Hemn Mohammadpour; Joseph L Sarow; Cameron R MacDonald; George L Chen; Jingxin Qiu; Umesh C Sharma; Xuefang Cao; Megan M Herr; Theresa E Hahn; Bruce R Blazar; Elizabeth A Repasky; Philip L McCarthy Journal: JCI Insight Date: 2020-06-18